Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) has just announced the result of its capital increase with preferential shareholders subscription rights through the issuance of new shares. The gross proceeds of this rights issue, issue premium included, totals €4.9 million. The primary purpose of the proceeds of this issuance of New Shares will be to provide the Company with additional resources to continue, over the next 12 months, the clinical development of its lead product candidate, setanaxib, in multiple fibrotic indications including primary biliary cholangitis (PBC, an orphan fibrotic disorder), idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease.